Latest & greatest articles for risperidone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on risperidone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on risperidone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for risperidone

81. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications

Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications Jerrell J M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of two novel antipsychotic medications, risperidone and olanzapine, to treat people diagnosed with schizophrenia and schizoaffective disorder. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients aged between 18 and 54 years old with a diagnosis of schizophrenia or schizoaffective

2002 NHS Economic Evaluation Database.

82. Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic

Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic Hosak L, Bahbouh R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of risperidone versus standard neuroleptics in the treatment of schizophrenia. Standard neuroleptics comprised a combination of chlorpromazine, chlorprothixene, haloperidol, levomepromazine, oxyprothepine, perfenazine and thioridazine. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients aged between 18 and 65 years

2002 NHS Economic Evaluation Database.

83. A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia

A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia Hansen K, Francois C, Toumi M, Lancon C Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three treatments for schizophrenia were examined: zuclopenthixol (ZUC), a neuroleptic belonging to the family of thioxanthenes, which are conventional agents; haloperidol (HAL), another conventional agent; and risperidone (RIS), a new combined two-serotonin and two

2002 NHS Economic Evaluation Database.

84. Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials

Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials Aleman A, Kahn R S Authors' objectives To evaluate the published evidence regarding the effects (...) of risperidone on hostility and aggression in schizophrenia. Searching MEDLINE and PsycLIT were searched from 1990 to June 2000. The search terms were 'risperidone', 'schizophrenia', 'aggression' and 'hostility'. Study selection Study designs of evaluations included in the review Only studies with a controlled design, i.e. placebo-control condition or typical antipsychotic control condition, were included. One trial was of 6 months' duration, one was 9 weeks, 4 were 8 weeks and one was 4 weeks. Specific

2001 DARE.

85. The clinical value of risperidone and olanzapine: a meta-analysis of efficacy and safety

The clinical value of risperidone and olanzapine: a meta-analysis of efficacy and safety The clinical value of risperidone and olanzapine: a meta-analysis of efficacy and safety The clinical value of risperidone and olanzapine: a meta-analysis of efficacy and safety Peuskens J, De Hert M, Jones M Authors' objectives To synthesise the clinical trial data currently available on two novel antipsychotics, risperidone and olanzapine, and to compare them with conventional products in terms (...) of efficacy and safety. Searching MEDLINE, EMBASE, and PsycLIT were searched for articles published between January 1991 and June 1998. The search terms included both brand and generic names of all known antipsychotic medications used for the treatment of human schizophrenia. Study selection Study designs of evaluations included in the review Only randomised controlled trials, which involved either a risperidone or an olanzapine arm, were included in the review. The included studies reported the mean

2001 DARE.

86. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia

Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia Oh P I, Lanctot K L, Mittmann N, Iskedjian M, Einarson T R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of risperidone (RIS) to ameliorate the negative symptoms of schizophrenia. Risperidone is a benzisoxazole derivative with combined serotonin and dopamine receptor blocking properties. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population

2001 NHS Economic Evaluation Database.

87. Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): health economic results of an international naturalistic study

Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): health economic results of an international naturalistic study Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): health economic results of an international naturalistic study Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): health economic results of an international naturalistic study Kasper S, Jones M, Duchesne I Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of either risperidone or olanzapine for the treatment of patients with schizophrenia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised hospitalised patients aged 65

2001 NHS Economic Evaluation Database.

88. Risperidone versus typical antipsychotic medication for schizophrenia. (PubMed)

Risperidone versus typical antipsychotic medication for schizophrenia. BACKGROUND: The 'conventional' neuroleptic drugs, such as haloperidol and chlorpromazine, are frequently used as the first line treatment for people with schizophrenia. However, about 5-25% of these people show poor response to these treatments and side effects often makes compliance with the 'older generation' of drug treatment problematic. Although the efficacy of these medications with respect to 'positive' symptoms (...) is well described, little evidence exists that 'conventional' antipsychotic treatment has any effect on the 'negative' symptoms of schizophrenia. Risperidone is one of the 'new generation' neuroleptic compounds. As well as its reputed tendency to cause fewer movement disorders it is claimed that risperidone may improve negative symptoms. OBJECTIVES: To evaluate the effectiveness of risperidone for schizophrenia in comparison to 'conventional' neuroleptic drugs. SEARCH STRATEGY: Electronic searches

2000 Cochrane

89. Risperidone versus other atypical antipsychotic medication for schizophrenia. (PubMed)

Risperidone versus other atypical antipsychotic medication for schizophrenia. BACKGROUND: Risperidone is one of a number of 'atypical antipsychotics' which are currently being marketed for the treatment of those with schizophrenia, largely on the basis of claims of improved tolerability and effectiveness compared to much cheaper conventional antipsychotics. The efficacy of risperidone has already been compared to conventional drugs, but it remains unclear how risperidone compares with other (...) atypical antipsychotic drugs such as clozapine. OBJECTIVES: To determine the effects of risperidone compared with other atypical antipsychotic drugs for schizophrenia. SEARCH STRATEGY: Electronic searches of Biological Abstracts (1980-1999), The Cochrane Library (Issue 1, 2000), The Cochrane Schizophrenia Group's Register (January 1999), EMBASE (1980-1999), MEDLINE (1966-1999), LILACS (1982-1999), PSYNDEX (1977-1999) and PsycLIT (1974-1999) were undertaken. In addition, pharmaceutical databases

2000 Cochrane

90. Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia

Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia Edgell E T, Andersen S W, Johnstone B M, Dulisse B, Revicki D, Breier A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of olanzapine, compared with risperidone, for the treatment of schizophrenia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients aged between 18 and 65 years who had been diagnosed

2000 NHS Economic Evaluation Database.

91. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials Efficacy and extrapyramidal side-effects of the new (...) antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials Leucht S, Pitschel-Walz G, Abraham D, Kissling W Authors' objectives To summarise the efficacy and tolerability of the new antipsychotics risperidone, olanzapine, sertindole and quetiapine in schizophrenia compared to placebo and conventional antipsychotics. Searching MEDLINE (1966-January 1998) and Current Contents (1966-March 1998) were

1999 DARE.

92. Treatment costs and patient outcomes with use of risperidone in a public mental health setting

Treatment costs and patient outcomes with use of risperidone in a public mental health setting Treatment costs and patient outcomes with use of risperidone in a public mental health setting Treatment costs and patient outcomes with use of risperidone in a public mental health setting Schiller M J, Shumway M, Hargreaves W A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Risperidone and standard antipsychotic medication in outpatient groups with schizophrenia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Adult schizophrenia or schizoaffective sufferers between 18 and 65 years old. Setting The setting for the study was the community and outpatient care. The economic analysis

1999 NHS Economic Evaluation Database.

93. Risperidone versus haloperidol - I: meta-analysis of efficacy and safety

Risperidone versus haloperidol - I: meta-analysis of efficacy and safety Risperidone versus haloperidol - I: meta-analysis of efficacy and safety Risperidone versus haloperidol - I: meta-analysis of efficacy and safety Davies A, Adena M A, Keks N A, Catts S V, Lambert T, Schweitzer I Authors' objectives To compare risperidone and haloperidol for the treatment of schizophrenia in terms of clinical response, prescription of anticholinergic agents and treatment drop-outs. Searching MEDLINE (...) and EMBASE were searched and enquiries were made to the manufacturer of risperidone. Study selection Study designs of evaluations included in the review Randomised double blind studies of at least 4 weeks duration that compared risperidone and haloperidol were included. Reasons were given for exclusion of identified studies. When more than one report used data from the same trial, the published version or the latest available report was selected. Specific interventions included in the review Risperidone

1998 DARE.

94. Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics

Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics Bech P, Peuskens J C, Marder S R, Chouinard G, Hoyberg O J, Huttunen M O, Blin O, Claus A Authors' objectives To assess (...) the benefits and the risks of treating chronic schizophrenia with risperidone or conventional neuroleptics. Searching Not stated. Publication dates of included studies ranged from 1992 to 1995. Study selection Study designs of evaluations included in the review Double-blind randomised controlled trials (RCTs). Follow-up ranged from 4 to 12 weeks. An intention-to-treat (last observation carried forward) analysis was performed. Specific interventions included in the review Risperidone (fixed dosage of 4mg

1998 DARE.

95. Economic outcomes associated with the use of risperidone in a naturalistic group practice setting

Economic outcomes associated with the use of risperidone in a naturalistic group practice setting Economic outcomes associated with the use of risperidone in a naturalistic group practice setting Economic outcomes associated with the use of risperidone in a naturalistic group practice setting Nightengale B S, Garrett L, Waugh S, Lawrence B J, Andrus J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Risperidone versus haloperidol in a naturalistic setting. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients over the age of 18 years suffering from either schizophrenia, schizoaffective disorder, or major depression with psychotic features. Setting The practice setting

1998 NHS Economic Evaluation Database.

96. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone

Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone Moore D B, Kelly D L, Sherr J D, Love R C, Conley R R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of atypical and depot antipsychotic agents was studied. The atypical agent was risperidone, whilst the depot agents were haloperidol decanoate or fluphenazine decanoate. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study

1998 NHS Economic Evaluation Database.

97. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia - summary

Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia - summary Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia - summary Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia - summary Glennie JL Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Glennie JL. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia - summary. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA). 1997 Authors' objectives To carry out a comparative therapeutic and economic evaluation of a) clozapine in treatment-resistantschizophrenic patients or those suffering

1997 Health Technology Assessment (HTA) Database.

98. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol

Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol Chouinard G, Albright P S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Risperidone or haloperidol for chronic schizophrenia sufferers. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population Patients with chronic schizophrenia who met DSMIII-R diagnostic criteria for the condition and had a total Positive and Negative Syndrome Scale (PANSS

1997 NHS Economic Evaluation Database.

99. Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety

Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety de Oliveira I R, Miranda-Scippa A M, de Sena E P, Pereira E L, Ribeiro M G, de Castro-e-Silva E, Bacaltchuk J Authors' objectives To compare (...) the short-term clinical efficacy and safety of risperidone with haloperidol and placebo. Searching MEDLINE was searched from 1988 to 1995 using the search terms given. The reference lists of the retrieved articles were also examined. Study selection Study designs of evaluations included in the review Double-blind randomised controlled trials (RCTs) were eligible for inclusion. Specific interventions included in the review Risperidone compared with haloperidol. The dose of risperidone ranged from 1 to 20

1996 DARE.

100. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retrospective analysis using the Saskatchewan health linkable databases

Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retrospective analysis using the Saskatchewan health linkable databases Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retrospective analysis using the Saskatchewan health linkable databases (...) Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retrospective analysis using the Saskatchewan health linkable databases Albright P S, Livingstone S, Keegan D L, Ingham M, Shrikhande S, Le Lorier J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods

1996 NHS Economic Evaluation Database.